Clinical trials
catalyst calendar across sponsors →Studies where ACTU is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 5 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Qube Research & Technologies Ltd) · FINRA short interest 2.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid TumorsNCT07714395To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and dose-limiting toxicities (DLTs) of elraglusib tabletsOpen-label · Treatment | Phase 1/2 | Not yet recruiting | Drug: Elraglusib Oral Tablets | Advanced Malignant Solid Tumor | 100 | Jul 2029 | ≤ 1,077 d | 2026-07-20 |
| 9-ING-41 in Patients With Advanced CancersNCT03678883Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan | Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma | 350 | Jun 2026 | — | 2026-04-03 |
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland CarcinomaNCT04832438Number of evaluable patients with objective response as measured by RECIST version 1.1Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Replaced by NCT05010629 | Drug: 9-ING-41, Carboplatin | Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Salivary Gland Neoplasms | 0 | 2033-06-18 | in 2,495 d | 2022-02-22 |
| 9-ING-41 in Pediatric Patients With Refractory Malignancies.NCT04239092Number of participants with treatment-related adverse events as assessed by CTCAE v5Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The decision to conclude study was made to optimize the clinical study design and protocol to further evaluate the safety profile of elraglusib (9-ING-41) in pediatric and adult patients with refractory Ewings Sarcoma. | Drug: 9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan | Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma | 40 | 2025-07-07actual | — | 2025-07-17 |
| Actuate 1901: 9-ING-41 in MyelofibrosisNCT04218071Response rateNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Ruxolitinib, 9-ING-41 | Myelofibrosis | 17 | 2022-10-13actual | — | 2024-02-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19